Anti-oncogenic activity of Chibby in the development of human nasopharyngeal carcinoma

Cai,Cheng‑Fu; Liu,Li‑Man; Shangguan,Han‑Jing; Liu,Cun‑Shan; Luo,Xian‑Yang; Li,Yi‑Meng

doi:10.3892/ol.2018.8009

Anti-oncogenic activity of Chibby in the development of human nasopharyngeal carcinoma

Authors:
- Cheng‑Fu Cai
- Li‑Man Liu
- Han‑Jing Shangguan
- Cun‑Shan Liu
- Xian‑Yang Luo
- Yi‑Meng Li
View Affiliations

Affiliations: Department of Otorhinolaryngology, Head and Neck Surgery, The First Affiliated Hospital, Medical College, Xiamen University, Xiamen, Fujian 361003, P.R. China, Institute of Stem Cell and Regeneration Medicine, Institutions of Biomedical Science, Fudan University, Shanghai 200031, P.R. China, Department of Otorhinolaryngology, Affiliated Eye and ENT Hospital of Fudan University, Shanghai 200031, P.R. China
Published online on: February 9, 2018 https://doi.org/10.3892/ol.2018.8009
Pages: 5849-5858

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The Wnt/β-catenin pathway serves important roles in cancer development. The expression and function of Chibby (Cby), as a direct antagonist of β‑catenin, in nasopharyngeal carcinoma (NPC) has not been fully investigated. The present study revealed that the mRNA and protein expression of Cby was significantly lower in NPC tissue than in the adjacent normal tissue. Low expression of Cby was significantly associated with the tumor and the clinical staging. Furthermore, Cby overexpression inhibited the proliferation of human NPC SUNE1 cells and induced cell cycle arrest. In addition, Cby overexpression also significantly enhanced the susceptibility of SUNE1 cells to apoptosis. These results indicated that Cby might serve as an anti-oncogenic gene in the development of NPC and could represent a potential therapeutic target for the human NPC therapy.

View Figures

View References

1	Wu VW and Lam YN: Radiation-induced temporo-mandibular joint disorder in post-radiotherapy nasopharyngeal carcinoma patients: Assessment and treatment. J Med RadiatSci. 63:124–132. 2016. View Article : Google Scholar
2	He YQ, Xue WQ, Shen GP, Tang LL, Zeng YX and Jia WH: Household inhalants exposure and nasopharyngeal carcinoma risk: A large-scale case-control study in Guangdong, China. BMC Cancer. 15:10222015. View Article : Google Scholar : PubMed/NCBI
3	Ng WT, Choi CW, Lee MC, Chan SH, Yau TK and Lee AW: Familial nasopharyngeal carcinoma in Hong Kong: Epidemiology and implication in screening. Fam Cancer. 8:103–108. 2009. View Article : Google Scholar : PubMed/NCBI
4	Mesic JB, Fletcher GH and Goepfert H: Megavoltage irradiation of epithelial tumors of the nasopharynx. Int J Radiat Oncol Biol Phys. 7:447–453. 1981. View Article : Google Scholar : PubMed/NCBI
5	Lee AW, Poon YF, Foo W, Law SC, Cheung FK, Chan DK, Tung SY, Thaw M and Ho JH: Retrospective analysis of 5037 patients with nasopharyngeal carcinoma treated during 1976–1985: Overall survival and patterns of failure. Int J Radiat Oncol Biol Phys. 23:261–270. 1992. View Article : Google Scholar : PubMed/NCBI
6	Chua DT, Sham JS, Wei WI, Ho WK and Au GK: The predictive value of the 1997 American joint committee on cancer stage classification in determining failure patterns in nasopharyngeal carcinoma. Cancer. 92:2845–2855. 2001. View Article : Google Scholar : PubMed/NCBI
7	Wolden SL, Zelefsky MJ, Kraus DH, Rosenzweig KE, Chong LM, Shaha AR, Zhang H, Harrison LB, Shah JP and Pfister DG: Accelerated concomitant boost radiotherapy and chemotherapy for advanced nasopharyngeal carcinoma. J ClinOncol. 19:1105–1110. 2001. View Article : Google Scholar
8	Takemaru K, Fischer V and Li FQ: Fine-tuning of nuclear-catenin by Chibby and 14-3-3. Cell cycle. 8:210–213. 2009. View Article : Google Scholar : PubMed/NCBI
9	Takemaru K, Yamaguchi S, Lee YS, Zhang Y, Carthew RW and Moon RT: Chibby, a nuclear beta-catenin-associated antagonist of the Wnt/Wingless pathway. Nature. 422:905–909. 2003. View Article : Google Scholar : PubMed/NCBI
10	Li FQ, Mofunanya A, Harris K and Takemaru K: Chibby cooperates with 14-3-3 to regulate beta-catenin subcellular distribution and signaling activity. J Cell Biol. 181:1141–1154. 2008. View Article : Google Scholar : PubMed/NCBI
11	Singh AM, Li FQ, Hamazaki T, Kasahara H, Takemaru K and Terada N: Chibby, an antagonist of the Wnt/beta-catenin pathway, facilitates cardiomyocyte differentiation of murine embryonic stem cells. Circulation. 115:617–626. 2007. View Article : Google Scholar : PubMed/NCBI
12	Li FQ, Singh AM, Mofunanya A, Love D, Terada N, Moon RT and Takemaru K: Chibby promotes adipocyte differentiation through inhibition of beta-catenin signaling. Mol Cell Biol. 27:4347–4354. 2007. View Article : Google Scholar : PubMed/NCBI
13	Love D, Li FQ, Burke MC, Cyge B, Ohmitsu M, Cabello J, Larson JE, Brody SL, Cohen JC and Takemaru K: Altered lung morphogenesis, epithelial cell differentiation and mechanics in mice deficient in the Wnt/β-catenin antagonist Chibby. PLoS One. 5:e136002010. View Article : Google Scholar : PubMed/NCBI
14	Korinek V, Barker N, Morin PJ, van Wichen D, de Weger R, Kinzler KW, Vogelstein B and Clevers H: Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/-colon carcinoma. Science. 275:1784–1787. 1997. View Article : Google Scholar : PubMed/NCBI
15	Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B and Kinzler KW: Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science. 275:1787–1790. 1997. View Article : Google Scholar : PubMed/NCBI
16	Schuierer MM, Graf E, Takemaru K, Dietmaier W and Bosserhoff AK: Reduced expression of beta-catenin inhibitor Chibby in colon carcinoma cell lines. World J Gastroenterol. 12:1529–1535. 2006. View Article : Google Scholar : PubMed/NCBI
17	Karakoula K, Suarez-Merino B, Ward S, Phipps KP, Harkness W, Hayward R, Thompson D, Jacques TS, Harding B, Beck J, et al: Real-time quantitative PCR analysis of pediatric ependymomas identifies novel candidate genes including TPR at 1q25 and CHIBBY at 22q12-q13. Genes Chromosomes Cancer. 47:1005–1022. 2008. View Article : Google Scholar : PubMed/NCBI
18	Fischer V, Brown-Grant DA and Li FQ: Chibby suppresses growth of human SW480 colon adenocarcinoma cells through inhibition of β-catenin signaling. J Mol Signal. 7:62012. View Article : Google Scholar : PubMed/NCBI
19	Mancini M, Leo E, Takemaru K, Campi V, Borsi E, Castagnetti F, Gugliotta G, Santucci MA and Martinelli G: Chibby drives β catenin cytoplasmic accumulation leading to activation of the unfolded protein response in BCR-ABL1+ cells. Cell Signal. 25:1820–1827. 2013. View Article : Google Scholar : PubMed/NCBI
20	Wang J and Zhu XZ: Introduction of WHO classification of tumours of soft tissue, the fourth edition. Zhonghua Bing Li XueZaZhi. 42:363–365. 2013.(In Chinese).
21	Jo VY and Fletcher CD: WHO classification of soft tissue tumours: An update based on the 2013 (4th) edition. Pathology. 46:95–104. 2014. View Article : Google Scholar : PubMed/NCBI
22	Mattern J, Koomagi R and Volm M: Biological characterization of subgroups of squamous cell lung carcinomas. Clin Cancer Res. 5:1459–1463. 1999.PubMed/NCBI
23	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
24	Gad S, Teboul D, Lièvre A, Goasguen N, Berger A, Beaune P and Laurent-Puig P: Is the gene encoding Chibby implicated as a tumour suppressor in colorectal cancer? BMC Cancer. 4:312004. View Article : Google Scholar : PubMed/NCBI
25	Duchartre Y, Kim YM and Kahn M: The Wnt signaling pathway in cancer. Crit Rev OncolHematol. 99:141–149. 2016. View Article : Google Scholar
26	Klaus A and Birchmeier W: Wnt signalling and its impact on development and cancer. Nat Rev Cancer. 8:387–398. 2008. View Article : Google Scholar : PubMed/NCBI
27	Takahashi-Yanaga F and Kahn M: Targeting Wnt signaling: Can we safely eradicate cancer stem cells? Clin Cancer Res. 16:3153–3162. 2010. View Article : Google Scholar : PubMed/NCBI
28	Yang D, Zhang M and Gold B: Origin of Somatic mutations in β-catenin versus adenomatous polyposis coli in colon cancer: Random mutagenesis in animal models versus nonrandom mutagenesis in humans. Chem Res Toxicol. 30:1369–1375. 2017. View Article : Google Scholar : PubMed/NCBI
29	Krishnamurthy N and Kurzrock R: Targeting the Wnt/beta-catenin pathway in cancer: Update on effectors and inhibitors. Cancer Treat Rev. 62:50–60. 2018. View Article : Google Scholar : PubMed/NCBI
30	Majidinia M, Aghazadeh J, Jahanban-Esfahlani R and Yousefi B: The roles of Wnt/β-catenin pathway in tissue development and regenerative medicine. J Cell Physiol. Nov 18–2017.(Epub ahead of print). View Article : Google Scholar
31	Polakis P: The many ways of Wnt in cancer. CurrOpin Genet Dev. 17:45–51. 2007. View Article : Google Scholar
32	He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, Morin PJ, Vogelstein B and Kinzler KW: Identification of c-MYC as a target of the APC pathway. Science. 281:1509–1512. 1998. View Article : Google Scholar : PubMed/NCBI
33	Tetsu O and McCormick F: Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature. 398:422–426. 1999. View Article : Google Scholar : PubMed/NCBI
34	Shtutman M, Zhurinsky J, Simcha I, Albanese C, D'Amico M, Pestell R and Ben-Ze'ev A: The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc Natl Acad Sci USA. 96:pp. 5522–5527. 1999; View Article : Google Scholar : PubMed/NCBI
35	Ren G, Zhao DA, Xu J and Li BA: Expression of CBY and methylation of CBY at promoter region in human laryngeal squamous cell carcinoma. Tumori. 101:215–222. 2015. View Article : Google Scholar : PubMed/NCBI
36	Fearon ER and Vogelstein B: A genetic model for colorectal tumorigenesis. Cell. 61:759–767. 1990. View Article : Google Scholar : PubMed/NCBI
37	Brabletz T, Jung A, Hermann K, Günther K, Hohenberger W and Kirchner T: Nuclear overexpression of the oncoprotein beta-catenin in colorectal cancer is localized predominantly at the invasion front. Pathol Res Pract. 194:701–704. 1998. View Article : Google Scholar : PubMed/NCBI
38	Monin MB, Krause P, Stelling R, Bocuk D, Niebert S, Klemm F, Pukrop T and Koenig S: The anthelmintic niclosamide inhibits colorectal cancer cell lines via modulation of the canonical and noncanonical Wnt signaling pathway. J Surg Res. 203:193–205. 2016. View Article : Google Scholar : PubMed/NCBI
39	Davidson G, Shen J, Huang YL, Su Y, Karaulanov E, Bartscherer K, Hassler C, Stannek P, Boutros M and Niehrs C: Cell cycle control of wnt receptor activation. Dev Cell. 17:788–799. 2009. View Article : Google Scholar : PubMed/NCBI
40	Drees F, Pokutta S, Yamada S, Nelson WJ and Weis WI: Alpha-catenin is a molecular switch that binds E-cadherin-beta-catenin and regulates actin-filament assembly. Cell. 123:903–915. 2005. View Article : Google Scholar : PubMed/NCBI
41	Wei WI and Sham JS: Nasopharyngeal carcinoma. Lancet. 365:2041–2054. 2005. View Article : Google Scholar : PubMed/NCBI